ClinicalTrials.gg
CompletedNCT02862548Updated Jun 8, 2022Results posted

Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant

A Phase 2 interventional study of TAF and TDF in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 1 site in New Zealand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-08.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic — 5 open to participants now, 10 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B, Chronic.

Enrollment
19th of 26
51 · median 124
Started
2016
with 1 other
Phase 2
4 of 26
none open now
Registered
2nd of 26
by date
Lead sponsor
5 of 26
Gilead Sciences

Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, this one is the 19th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 2nd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

5 of the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tenofovir alafenamide

tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF)-containing regimens at Week 24 in participants with chronic hepatitis B virus (HBV) infection and Stage 2 or greater chronic kidney disease who have received a liver transplant.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have the ability to understand and sign a written form; consent must be obtained prior to initiation of study procedures
  • Documented evidence of chronic infection prior to transplantation
  • Primary or secondary (re-transplant), liver alone or liver and kidney transplant recipient from deceased or living donor
  • Liver Transplant ≥ 12 weeks prior to screening
  • Maintained on TDF alone or in combination with other approved antivirals for HBV prophylaxis or treatment
  • Have been on approved HBV oral antiviral (OAV) treatment for at least 12 weeks post-transplant prior to screening, with HBV DNA \< lower limit of quantification (LLOQ) at screening
  • Screening estimated using the chronic kidney disease epidemiology collaboration (eGFR_CKD-EPI) \< 90 ml/min/1.73m\^2
  • Male participants and female participants of who engage in heterosexual intercourse must agree to use protocol specified method(s) of
  • Women considered of child bearing potential must have a negative serum pregnancy test at Screening and a negative urine test at Baseline before dosing
  • Must be willing and able to comply with all study requirements

Key Exclusion Criteria:

  • Multi-organ transplant that includes heart or lung recipient (participants who have their liver transplant as part of a liver-kidney dual transplant are eligible to enroll)
  • Participants with history of de novo or recurrent hepatocellular carcinoma (HCC) post-transplant and at screening
  • Histological evidence of unresolved transplant rejection
  • Current, uncontrolled ascites, variceal hemorrhage, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome, or other signs of decompensated cirrhosis
  • Participants meeting any of the following laboratory parameters at screening:

    • (ALT) > 10 × the (ULN)
    • (INR) > 1.5 × ULN unless the participant is stable on anticoagulant regimen affecting INR
    • Albumin \< 3.0 g/dL
    • Direct ≥ 4 × ULN
    • count \< 50,000/mL
  • Co-infection with or virus (HCV)
  • Recent (within 4 weeks of Screening) episode or infection requiring systemic antibiotics
  • Use of any prohibited medications listed within 28 days of the Baseline/Day 1 visit
  • within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (e.g., basal cell skin cancer, etc.) or hepatocellular carcinoma. Participants under evaluation for possible malignancy are not eligible
  • Significant cardiovascular, pulmonary, or neurological disease
  • Use of agents within 3 months of screening, unless allowed by the Sponsor
  • Use of any prohibited medications
  • Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance
  • Known to study drugs, metabolites or formulation
  • Lactating females or those who may wish to become pregnant during the course of the study

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    TAF

    TAF 25 mg once daily for 48 weeks

    Drug: TAF

  • Active comparator
    TDF-Containing Regimens

    TDF alone or in combination with other approved antivirals per local practice for 48 weeks

    Drug: TDF · Drug: Other approved antivirals

  • Experimental
    Optional Treatment Extension Phase

    After Week 48, participants will be eligible to receive TAF 25 mg once daily for an additional 144 weeks.

    Drug: TAF

Interventions

  • DrugTAF

    Tablet administered orally

    Also known as: Vemlidy®

  • DrugTDF

    Tablet administered orally

  • DrugOther approved antivirals

    Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation

    Time frame: Baseline, Week 24

  2. Percentage of Participants With HBV DNA < 20 IU/mL at Week 24

    Time frame: Week 24

Secondary outcomes

  1. Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24

    Time frame: Baseline, Week 24

  2. Percent Change From Baseline in Hip BMD at Week 48

    Time frame: Baseline, Week 48

  3. Percent Change From Baseline in Spine BMD at Week 24

    Time frame: Baseline, Week 24

  4. Percent Change From Baseline in Spine BMD at Week 48

    Time frame: Baseline, Week 48

  5. Change From Baseline in Serum Creatinine at Week 24

    Time frame: Baseline, Week 24

  6. Change From Baseline in Serum Creatinine at Week 48

    Time frame: Baseline, Week 48

  7. Change From Baseline in Serum eGFR_CKD-EPI at Week 48

    Time frame: Baseline, Week 48

  8. Percentage of Participants With HBV DNA < 20 IU/mL at Week 48

    Time frame: Week 48

07

Results

Posted Feb 26, 2019

Participant flow

Participants were enrolled at a study site in New Zealand. The first participant was screened on 16 September 2016. The last study visit occurred on 05 May 2021.

Randomized Phase (Up to Week 48)
Participant flow — Randomized Phase (Up to Week 48)
MilestoneTAF 25 mgTDF-Containing Regimens
Started2625
Completed2624
Not completed01
Withdrew: Death01
OLE Phase (Week 49 to Week 192)
Participant flow — OLE Phase (Week 49 to Week 192)
MilestoneTAF 25 mgTDF-Containing Regimens
Started2624
Completed2323
Not completed31
Withdrew: Death20
Withdrew: Adverse event10
Withdrew: Withdrew consent01

Outcome measures

PrimaryChange From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation
Time frame:
Baseline, Week 24
Reported as:
Mean · mL/min/1.73 m^2
Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation
mL/min/1.73 m^2TAF 25 mgTDF-Containing Regimens
Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation2.13 ± 6.0111.87 ± 6.553
PrimaryPercentage of Participants With HBV DNA < 20 IU/mL at Week 24
Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < 20 IU/mL at Week 24
percentage of participantsTAF 25 mgTDF-Containing Regimens
Percentage of Participants With HBV DNA < 20 IU/mL at Week 24100.0100.0
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24
percent changeTAF 25 mgTDF-Containing Regimens
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 240.478 ± 1.63420.452 ± 2.1380
SecondaryPercent Change From Baseline in Hip BMD at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Hip BMD at Week 48
percent changeTAF 25 mgTDF-Containing Regimens
Percent Change From Baseline in Hip BMD at Week 481.253 ± 1.9774-0.413 ± 2.6361
SecondaryPercent Change From Baseline in Spine BMD at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 24
percent changeTAF 25 mgTDF-Containing Regimens
Percent Change From Baseline in Spine BMD at Week 240.799 ± 2.5563-0.188 ± 2.5890
SecondaryPercent Change From Baseline in Spine BMD at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 48
percent changeTAF 25 mgTDF-Containing Regimens
Percent Change From Baseline in Spine BMD at Week 481.454 ± 4.5405-1.082 ± 3.0031
SecondaryChange From Baseline in Serum Creatinine at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 24
mg/dLTAF 25 mgTDF-Containing Regimens
Change From Baseline in Serum Creatinine at Week 24-0.043 ± 0.1434-0.040 ± 0.1623
SecondaryChange From Baseline in Serum Creatinine at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 48
mg/dLTAF 25 mgTDF-Containing Regimens
Change From Baseline in Serum Creatinine at Week 48-0.052 ± 0.2233-0.058 ± 0.2158
SecondaryChange From Baseline in Serum eGFR_CKD-EPI at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · mL/min/1.73 m^2
Change From Baseline in Serum eGFR_CKD-EPI at Week 48
mL/min/1.73 m^2TAF 25 mgTDF-Containing Regimens
Change From Baseline in Serum eGFR_CKD-EPI at Week 483.01 ± 9.3852.09 ± 9.209
SecondaryPercentage of Participants With HBV DNA < 20 IU/mL at Week 48
Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < 20 IU/mL at Week 48
percentage of participantsTAF 25 mgTDF-Containing Regimens
Percentage of Participants With HBV DNA < 20 IU/mL at Week 48100.088.0

Adverse events

Collected over All-Cause Mortality: Randomization up to last follow up visit (maximum 236.7 weeks); Adverse Events: First dose date up to last dose date plus 30 days (maximum 225.9 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Phase: TAF 25 mg0/26 (0%)3/26 (11.5%)19/26 (73.1%)
Randomized Phase: TDF-Containing Regimens1/25 (4%)7/25 (28%)17/25 (68%)
OLE Phase: TAF 25 mg From TAF2/26 (7.7%)8/26 (30.8%)22/26 (84.6%)
OLE Phase: TAF 25 mg From TDF0/24 (0%)8/24 (33.3%)21/24 (87.5%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventRandomized Phase: TAF 25 mgRandomized Phase: TDF-Containing RegimensOLE Phase: TAF 25 mg From TAFOLE Phase: TAF 25 mg From TDF
Acute kidney injuryRenal and urinary disorders0/260/251/264/24
Atrial fibrillationCardiac disorders0/260/250/262/24
DiarrhoeaGastrointestinal disorders0/260/250/262/24
Lower respiratory tract infectionInfections and infestations2/260/251/262/24
UrosepsisInfections and infestations0/260/250/262/24
CholangitisHepatobiliary disorders1/262/252/261/24
CellulitisInfections and infestations0/261/252/261/24
PneumoniaInfections and infestations0/261/252/260/24
AnaemiaBlood and lymphatic system disorders0/260/250/261/24
ColitisGastrointestinal disorders0/260/250/261/24
Most frequent other events
Showing 10 of 33
Most frequent other events
EventRandomized Phase: TAF 25 mgRandomized Phase: TDF-Containing RegimensOLE Phase: TAF 25 mg From TAFOLE Phase: TAF 25 mg From TDF
Influenza like illnessGeneral disorders2/265/251/262/24
ArthralgiaMusculoskeletal and connective tissue disorders0/262/255/261/24
CoughRespiratory, thoracic and mediastinal disorders4/262/255/263/24
Back painMusculoskeletal and connective tissue disorders4/261/251/261/24
MyalgiaMusculoskeletal and connective tissue disorders0/260/254/260/24
HeadacheNervous system disorders4/262/250/260/24
Vitamin D deficiencyMetabolism and nutrition disorders0/260/250/263/24
LethargyNervous system disorders2/262/252/263/24
PyrexiaGeneral disorders3/263/250/260/24
Abdominal distensionGastrointestinal disorders3/261/250/260/24

Baseline characteristics

Safety Analysis Set included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)TAF 25 mgTDF-Containing RegimensTotal
Mean58 ± 12.662 ± 8.360 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)TAF 25 mgTDF-Containing RegimensTotal
Female10313
Male162238
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TAF 25 mgTDF-Containing RegimensTotal
Hispanic or Latino000
Not Hispanic or Latino262551
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TAF 25 mgTDF-Containing RegimensTotal
Race — Asian71017
Race — Black or African American101
Race — Native Hawaiian or Pacific Islander151227
Race — White235
Race — Other101
Region of Enrollment
Region of Enrollment(Participants)TAF 25 mgTDF-Containing RegimensTotal
New Zealand262551
HBV Deoxy Ribonucleic Acid (DNA)
HBV Deoxy Ribonucleic Acid (DNA)(International unit per mL (IU/mL))TAF 25 mgTDF-Containing RegimensTotal
Mean19.0 ± 0.0019.0 ± 0.0019.0 ± 0.00
eGFR by CKD-EPI Creatinine
eGFR by CKD-EPI Creatinine(mL/minute/1.73 square meter(m^2))TAF 25 mgTDF-Containing RegimensTotal
Median52.3 ± 12.3152.4 ± 12.7452.4 ± 12.40
08

Study locations

1 site
  • Auckland City Hospital
    Auckland, New Zealand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Feb 2018, 16 months.

Results were first posted in Feb 2019, 1 year after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 16 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2016
First posted
Aug 11, 2016
StartActual
Sep 16, 2016
Primary completionActual
Feb 8, 2018
CompletionActual
May 5, 2021
Results first posted
Feb 26, 2019
Last update
Jun 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02862548
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 11, 2016
Start date
Sep 16, 2016
Primary completion
Feb 8, 2018
Completion
May 5, 2021
Results posted
Feb 26, 2019
Last update
Jun 8, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion